PDS Planning’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.7M | Sell |
108,916
-1,617
| -1% | -$359K | 1.56% | 14 |
|
|
2025
Q4 | $25.3M | Buy |
110,533
+2,541
| +2% | +$579K | 1.69% | 15 |
|
|
2025
Q3 | $25M | Buy |
107,992
+88
| +0.1% | +$17.9K | 1.73% | 15 |
|
|
2025
Q2 | $20M | Buy |
107,904
+442
| +0.4% | +$82.1K | 1.49% | 15 |
|
|
2025
Q1 | $22.5M | Buy |
107,462
+361
| +0.3% | +$70.2K | 1.9% | 13 |
|
|
2024
Q4 | $19M | Sell |
107,101
-1,401
| -1% | -$258K | 1.69% | 13 |
|
|
2024
Q3 | $21.4M | Buy |
108,502
+4,623
| +4% | +$863K | 1.92% | 13 |
|
|
2024
Q2 | $17.8M | Buy |
103,879
+308
| +0.3% | +$51K | 1.8% | 13 |
|
|
2024
Q1 | $18.9M | Buy |
103,571
+34
| +0% | +$5.86K | 1.98% | 12 |
|
|
2023
Q4 | $16M | Buy |
103,537
+342
| +0.3% | +$49.9K | 1.83% | 13 |
|
|
2023
Q3 | $15.4M | Sell |
103,195
-7,504
| -7% | -$1.1M | 1.99% | 12 |
|
|
2023
Q2 | $14.9M | Sell |
110,699
-12,890
| -10% | -$1.89M | 1.91% | 13 |
|
|
2023
Q1 | $19.7M | Buy |
123,589
+1,346
| +1% | +$206K | 2.72% | 11 |
|
|
2022
Q4 | $19.8M | Sell |
122,243
-667
| -0.5% | -$102K | 3.16% | 9 |
|
|
2022
Q3 | $16.5M | Sell |
122,910
-563
| -0.5% | -$80.8K | 3% | 12 |
|
|
2022
Q2 | $18.9M | Buy |
123,473
+1,721
| +1% | +$263K | 3.42% | 9 |
|
|
2022
Q1 | $19.7M | Buy |
121,752
+10,600
| +10% | +$1.54M | 3.47% | 10 |
|
|
2021
Q4 | $15.1M | Buy |
111,152
+28,572
| +35% | +$3.38M | 2.88% | 12 |
|
|
2021
Q3 | $8.91M | Sell |
82,580
-97
| -0.1% | -$11.1K | 2.06% | 13 |
|
|
2021
Q2 | $9.31M | Buy |
82,677
+464
| +0.6% | +$52.3K | 2.27% | 13 |
|
|
2021
Q1 | $8.9M | Sell |
82,213
-7
| -0% | -$749 | 2.58% | 10 |
|
|
2020
Q4 | $8.81M | Buy |
82,220
+589
| +0.7% | +$56.6K | 3.02% | 9 |
|
|
2020
Q3 | $7.15M | Buy |
81,631
+52
| +0.1% | +$4.9K | 2.91% | 10 |
|
|
2020
Q2 | $8.01M | Buy |
81,579
+435
| +0.5% | +$38.3K | 3.63% | 7 |
|
|
2020
Q1 | $6.18M | Buy |
81,144
+12
| +0% | +$1.02K | 3.95% | 7 |
|
|
2019
Q4 | $7.18M | Sell |
81,132
-369
| -0.5% | -$30.6K | 4.53% | 5 |
|
|
2019
Q3 | $6.17M | Sell |
81,501
-209
| -0.3% | -$14.3K | 4.28% | 6 |
|
|
2019
Q2 | $5.94M | Buy |
81,710
+468
| +0.6% | +$36.8K | 4.42% | 6 |
|
|
2019
Q1 | $6.55M | Sell |
81,242
-344
| -0.4% | -$28.1K | 5.09% | 4 |
|
|
2018
Q4 | $7.52M | Sell |
81,586
-2,803
| -3% | -$246K | 6.46% | 2 |
|
|
2018
Q3 | $7.98M | Buy |
84,389
+810
| +1% | +$76.8K | 6.83% | 2 |
|
|
2018
Q2 | $7.74M | Buy |
83,579
+2,378
| +3% | +$232K | 7.64% | 2 |
|
|
2018
Q1 | $7.69M | Sell |
81,201
-6,908
| -8% | -$759K | 7.77% | 2 |
|
|
2017
Q4 | $8.52M | Buy |
+88,109
| New | +$8.3M | 8.63% | 2 |
|
Other funds holding ABBV
VCM
VPM
PDS Planning's ABBV Position: Q1 2026 in Review
PDS Planning reduced its AbbVie (ABBV) stake by 1.5% in Q1 2026, selling an estimated $359K and leaving 108,916 shares worth $23.7M. The position accounts for 1.56% of the portfolio, ranked #14.
PDS Planning first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $25.3M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- PDS Planning held 108,916 shares of AbbVie worth $23.7M as of Q1 2026.
- PDS Planning sold 1,617 AbbVie shares in Q1 2026, an estimated $359K.
- AbbVie made up 1.56% of PDS Planning's portfolio in Q1 2026, its #14 holding.
- PDS Planning first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- PDS Planning's AbbVie position peaked at $25.3M in Q4 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on PDS Planning's 13F filing for Q1 2026, filed 22 Apr 2026.